Palisade Bio Inc - PALI STOCK NEWS

Palisade Bio (Nasdaq: PALI) reported its Q1 2022 financial results, showing a net loss of $4.2 million, consistent with $4.0 million in Q1 2021. The company has increased R&D expenses by 39% to $1.0 million due to advancing clinical trials. Significant advances include FDA and NMPA clearance to initiate Phase 3 trials for LB1148, targeting postoperative bowel function recovery. Additionally, a $2.0 million direct offering extended their cash runway. LB1148 showed a 93% reduction in post-surgical adhesions during studies. Upcoming milestones include the start of U.S. Phase 3 trials in Q2 2022.

Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company, announced equity grants to four new non-executive employees under its 2021 Inducement Plan. On May 4, 2022, the Compensation Committee granted options covering a total of 140,000 shares of common stock, with an exercise price equal to the closing price on the grant date. The options vest quarterly over three years, contingent on continued employment. Palisade Bio focuses on therapies for gastrointestinal complications, with its lead asset, LB1148, progressing toward Phase 3 trials, showing promise in improving bowel function and reducing hospital stays.

Palisade Bio, Inc. (Nasdaq: PALI) announced a registered direct offering of 3,646,690 shares of common stock at $0.55 per share, raising capital for working and corporate purposes, including the development of its lead product candidate, LB1148. The offering, facilitated by Ladenburg Thalmann & Co. Inc., is expected to close around May 10, 2022. Investors will also receive unregistered warrants to purchase the same number of shares at $0.7105, expiring in five and a half years. The offering is conducted under an effective SEC registration statement.

Palisade Bio (PALI) has secured clearance from the NMPA in China to initiate a Phase 3 clinical trial for LB1148, aimed at expediting bowel function recovery in patients undergoing abdominal surgery. This follows recent FDA clearance for the same Phase 3 study in the U.S. LB1148, an oral serine protease inhibitor, showed statistically significant results in a previous Phase 2 trial. Newsoara Biopharma will fully fund the Phase 3 program in China and trigger milestone payments upon achieving specific goals.

Palisade Bio (Nasdaq: PALI) is set to commence a Phase 3 clinical trial for its lead product, LB1148, aimed at enhancing postoperative bowel function, in Q2 2022. The therapy is designed to mitigate gastrointestinal complications by inhibiting digestive proteases during surgery, potentially reducing hospital stays and abdominal adhesions. A recent study demonstrated a 72% decrease in adhesion incidence among patients treated with LB1148. The FDA granted Fast Track designation for LB1148, reflecting its importance in surgical recovery.

Palisade Bio (Nasdaq: PALI) will host a virtual investor management and KOL roundtable on May 3, 2022, at 10:00 AM ET. Management team members, including CEO Tom Hallam, CMO Michael Dawson, and VP Robert McRae, will participate alongside Key Opinion Leader Dr. David B. Hoyt. The event will cover intestinal barrier health and Palisade's targeted therapeutics for gastrointestinal complications. A live video webcast will be available on the company's investor page, with a replay accessible for 90 days.

LB1148, Palisade's lead asset, aims to reduce abdominal adhesions and restore bowel function post-surgery.

Palisade Bio, a clinical stage biopharmaceutical company focused on therapies for gastrointestinal complications, will participate in the 2022 Virtual Growth Conference from March 28-30, 2022. The conference, organized by Maxim Group LLC, offers a platform for multiple sectors, including Biotech and Healthcare. A video webcast of Palisade's presentation will be available on-demand. Notably, the company is advancing its lead asset, LB1148, which demonstrated promising results in Phase 2 trials and is set to enter Phase 3 in late 2022.

Palisade Bio, a clinical stage biopharmaceutical company, has received a "Study May Proceed" letter from the FDA for its Phase 3 trial of LB1148. This trial aims to evaluate LB1148's ability to accelerate bowel function recovery in patients after abdominal surgery. Approximately 600 subjects will be enrolled in this double-blinded, placebo-controlled study. Previous Phase 2 trials demonstrated LB1148's effectiveness in improving GI function and patient outcomes. Palisade plans to commence the trial in the latter half of 2022, highlighting LB1148's potential to benefit post-surgical patients significantly.

Palisade Bio, Inc. (Nasdaq: PALI) reported significant advancements in its clinical programs and financial results for the year ended December 31, 2021. The merger with Seneca and a $22 million financing provided essential capital to support clinical development. Positive Phase 2 results for LB1148 showed a 1.1-day acceleration in bowel function return after GI surgery, prompting progression to Phase 3 studies.

Furthermore, LB1148 received FDA Fast Track designation for treatment indications, enhancing its development prospects. As of year-end 2021, Palisade held $10.5 million in cash and reduced R&D expenses.